ArticleCommunications medicine2025
Association of leukocyte composition ratios from blood methylation with cancer mortality outcomes.
Article in Communications medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLeukocyte composition ratios derived from blood genome-wide methylation (DNAm-derived LCRs), reflecting systemic inflammation, remain unclear in relation to various mortality outcomes.
methodsWe performed an epigenome-wide analysis to identify the association of DNAm-derived LCRs with all-cause mortality, cancer-specific mortality, and lung-cancer-specific mortality in a large prospective cohort study with 17 years follow-up.
resultsStrong associations of multiple LCRs are seen for all mortality outcomes. The neutrophil-to-B-cell ratio was strongly associated with all-cause mortality (HR per SD increase, 1.20; 95% CI, 1.10-1.31), the neutrophil-to-lymphocyte ratio with cancer-specific mortality (HR, 1.28; 1.11-1.49), and the lymphocyte-to-monocyte ratio with lung-cancer-specific mortality (HR, 0.53; 0.38-0.75). The consistency of HR estimations across 11-year, 14-year, and 17-year follow-ups reinforces these findings. Several LCRs show stronger associations in females and younger participants.
conclusionsOur study identifies DNAm-derived LCRs as particularly useful measures for quantifying cancer mortality risk over long-term follow-ups exceeding a decade.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.